| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 03/21/2002 | WO2002022559A2 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022557A2 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022170A1 Insulin secretion controlling agents |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022163A1 Remedies for ischemic diseases |
| 03/21/2002 | WO2002022151A2 Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| 03/21/2002 | WO2002022139A1 Intraarticular agent for the treatment of osteoarthritis |
| 03/21/2002 | WO2002022136A1 Diphosphonate solutions |
| 03/21/2002 | WO2002022124A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022119A1 Use of rhein for preparing a medicine for preventing articular cartilage damage |
| 03/21/2002 | WO2002022113A2 Retinoic acid receptor antagonists as promoters of angiogenesis |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022108A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 03/21/2002 | WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001078702A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001074379A3 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 03/21/2002 | WO2001074365A3 An efficacious dosage regimen of galantamine that reduces side effects |
| 03/21/2002 | WO2001068568A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001068074A3 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001062942A3 MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
| 03/21/2002 | WO2001062905A3 Integrin antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001043732A3 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| 03/21/2002 | WO2001030375A3 Use of gdnf for treating corneal defects |
| 03/21/2002 | WO2001003774A3 Pharmaceutical composition for the treatment of calcification |
| 03/21/2002 | US20020035737 Cloning pigs using donor nuclei from differentiated cells |
| 03/21/2002 | US20020035402 Osteoinductive ceramic materials |
| 03/21/2002 | US20020035243 Drug complexes |
| 03/21/2002 | US20020035161 O/W emulsions comprising micronized biologically active agents |
| 03/21/2002 | US20020035147 Nervous system, psychological disorders |
| 03/21/2002 | US20020035144 Solubility, bioavailability; antiinflammatory agents |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035104 Integrin receptor inhibitors |
| 03/21/2002 | US20020035094 Substituted pyridine compounds and methods of use |
| 03/21/2002 | US20020035092 Propanoic acid derivatives |
| 03/21/2002 | US20020035074 Administering isoflavone formononetin, or isoflavone daidzein |
| 03/21/2002 | US20020035065 Selective MMP inhibitors having reduced side-effects |
| 03/21/2002 | US20020034764 Diarylsulfonylurea binding proteins |
| 03/21/2002 | US20020034537 For enhancing selective delivery of therapeutic, diagnostic and imaging agents to activated vascular sites |
| 03/21/2002 | US20020034534 Receptor loading dosage form containing therapeutic agent and extended-release dosage form containing therapeutic agent administered concurrently |
| 03/21/2002 | US20020033144 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| 03/21/2002 | DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3 |
| 03/21/2002 | CA2432780A1 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f25g(a) antagonists |
| 03/21/2002 | CA2422828A1 Novel tumor-associated marker |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422426A1 Polymorphic bone morphogenetic protein 2 |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422233A1 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2aantagonists |
| 03/21/2002 | CA2422137A1 Tetrahydroquinoline compounds |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422093A1 Use of rhein for preparing a medicine for preventing articular cartilage damage |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422064A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 03/21/2002 | CA2421966A1 Remedies for ischemic diseases |
| 03/21/2002 | CA2421792A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421652A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2421234A1 Interferon-alpha induced gene |
| 03/21/2002 | CA2420529A1 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420007A1 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2419219A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/21/2002 | CA2406446A1 Diphosphonate solutions |
| 03/21/2002 | CA2357467A1 Methods for treating osteoarthritis using an estrogen agonist/antagonist |
| 03/20/2002 | EP1188761A1 Novel geminal-diphosphonic acids and their manufacture |
| 03/20/2002 | EP1188754A1 Substituted pyrazole compounds |
| 03/20/2002 | EP1188440A1 Medicinal composition for oral administration |
| 03/20/2002 | EP1188438A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187838A1 Thiazolopyrimidines useful as tnf-alpha inhibitors |
| 03/20/2002 | EP1187836A1 Substituted imidazothiazoles as antidepressant agents |
| 03/20/2002 | EP1187817A1 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same |
| 03/20/2002 | EP1187816A1 5-cyano-2-aminopyrimidine derivatives |
| 03/20/2002 | EP1187815A1 4-phenyl-pyrimidine derivatives |
| 03/20/2002 | EP1187813A1 Azolylbenzamides and analogues and their use for treating osteoporosis |
| 03/20/2002 | EP1187811A1 Inhibitors of metalloproteinases |
| 03/20/2002 | EP1187636A1 Injectable hyaluronate-sulfated polysaccharide conjugates |
| 03/20/2002 | EP1187624A1 Conformationally constrained backbone cyclized interleukin-6 antagonists |
| 03/20/2002 | EP1187620A1 Antisense modulation of b7 protein expression |
| 03/20/2002 | EP1187618A1 Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
| 03/20/2002 | EP1187592A2 Alpha v integrin receptor antagonists |
| 03/20/2002 | EP0837860B1 TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO(3,4-c]-1,2,4-TRIAZOLO(4,3-ALPHA]PYRIDINES |
| 03/20/2002 | EP0625043B1 Recombinant multivalent m protein vaccine |
| 03/20/2002 | CN1341120A 骨刺激因子 Bone stimulator |
| 03/20/2002 | CN1341103A Pyridazin-3-one derivatives and medicines containing the same |
| 03/20/2002 | CN1341099A 2-aminopyridines containing fused ring substituents |
| 03/20/2002 | CN1341026A Small peptides and methods for treatment of asthma and inflammation |
| 03/20/2002 | CN1340354A Liquid medicine 'Erhu tendon-setting liquid' |
| 03/20/2002 | CN1340349A Chinese medicine for treating hyperosteogeny and rheumatism |
| 03/20/2002 | CN1340345A Orally-applied medicine for treating hyperosteogeny |
| 03/20/2002 | CN1081058C Chinese-medicinal band for therapy |
| 03/20/2002 | CN1081053C External use medicinal ointment for curing prolapse of lumbar intervertebral disc and preparing process thereof |